Phase II year
2008
(last award dollars: 2013)
Phase II Amount
$3,202,953
As of 2003 the CDC estimated that there were approximately 1.1 million persons in the U.S. infected with HIV- 1 and about 40,000 new cases are diagnosed each year. During the mid-to-late 1990s, advances in treatment slowed the progression of HIV to AIDS and related deaths. Unfortunately, the treatment often leads to the emergence of drug resistant mutants of HIV-1. The knowledge of the HIV-1 variants present in a patient is extremely important to effectively plan disease management. It is estimated that about 8% of HIV-1 infections in the US is caused by drug resistant HIV-1 variants and current guidelines recommend HIV-1 resistance genotyping before therapy and to monitor therapy effectiveness. However, current tests that rely on conventional DNA sequencing methods do not detect low-levels (
Public Health Relevance: This Public Health Relevance is not available.
Thesaurus Terms: Genotype Aids, Dna, Dna Directed Dna Polymerase, Haart (Highly Active Antiretroviral Therapy), Rna, Rna Directed Dna Polymerase, Alkyne, Azide, Base, Carbamate, Cell, Chemical Cleavage, Chemistry, Chemotherapy, Conditioning, Death, Density, Drug Resistance, Endopeptidase, Ether, Fluorescent Dye /Probe, Gene, Glass, Infection, Ionophore, Lead, Material, Model, Mutant, Nucleic Acid Sequence, Nucleotide, Optics, Performance, Plasma, Plasmid, Plastic, Reading, Temperature, Therapy, Transfection /Expression Vector